Seamless Therapeutics, a pioneering biotechnology firm based in Dresden, Germany, has secured $12.5M in Seed funding to propel its groundbreaking recombinase platform. Led by esteemed investors Wellington Partners and Forbion, alongside non-dilutive funding from BMBF GO-Bio, this investment marks a significant milestone in the company's journey.

The infusion of capital will fuel the advancement of Seamless Therapeutics' proprietary technology platform, accelerating the development of a robust pipeline of therapeutic candidates poised for first-in-human trials. Moreover, the company aims to expand its footprint across the EU and US markets, further cementing its position as a leader in gene editing solutions.

Under the visionary leadership of CEO Anne-K. Heninger and CSO Felix Lansing, Seamless Therapeutics is revolutionizing the landscape of disease modification. Leveraging its innovative platform, the company is pioneering a diverse range of therapeutic interventions spanning various indications, unlocking the full potential of gene editing technology.

At the core of Seamless Therapeutics' approach lies its proprietary recombinase platform, which enables precise and targeted modifications to the genome. By reprogramming site-specific recombinases, the company empowers researchers to enact a spectrum of genetic alterations, from small-scale modifications to large-scale DNA rearrangements. This unprecedented level of programmability heralds a new era in genome editing, offering unparalleled flexibility and efficacy in therapeutic development.

With a focus on expanding the therapeutic potential of gene editing, Seamless Therapeutics is poised to address unmet medical needs across diverse disease areas. By harnessing the power of recombinase technology, the company endeavors to redefine the treatment landscape, offering hope to patients and clinicians alike.

As investors, now is the time to seize the opportunity and join Seamless Therapeutics on its transformative journey. With a proven track record of innovation and a commitment to excellence, the company stands at the forefront of the biotechnology revolution. Invest in Seamless Therapeutics today and be part of shaping the future of medicine.